Abstract��
Objective To describe the important role of cationic peptides in the treatment of central nervous system diseases. Methods The related literature at home and abroad in recent years were read sorted and summarized. The penetration of cationic peptide modified drug carrier system through the blood brain barrier and its important role in the treatment of central nervous system diseases were comprehensively introduced. Results AND Conclusion Cationic peptide as a member of cell membrane peptides family and also the most commonly used peptide, has an important role in the transport of drugs blood brain through blood brain barrier. It has made a significant contribution to the therapy of central nervous system diseases.
WANG Yu-Hua,
TIAN Xin-Hua-*,
WEI Feng
.Application of Cationic Peptides in Treatment of Central Nervous System Disease[J] Chinese Pharmaceutical Journal, 2013,V48(13): 1123-1125
��
[1]
REMPE R, CRAMER S, HÜWEL S, et al. Transport of Poly(n-butylcyano-acrylate) nanoparticles across the blood-brain barrier in vitro and their influence on barrier integrity. Biochemical and Biophysical Research Communications, 2011,406(1): 64-69.
[2]
QIN Y, CHEN H, ZHANG Q,et al. Liposome formulated with TAT-modified cholesterol for improving brain delivery and therapeutic efficacy on brain glioma in animals. Int J Pharm, 2011, 420(2):304-312.
[3]
ZHANG X B,XIE J Q,HOU X P. Effects of Cereport and its derivative on the transporting of amphotericin B liposome across the blood brain barrier of rats.Chin Pharm J(�й�ҩѧ��־), 2003,38(08): 598-601.
[4]
LEE J H, SONG H S, LEE S G, et al. Screening of cell-penetrating peptides(CPPs) using mRNA display. Biotechnol, 2012,7(3):387-396.
[5]
WANG P, LIU M, GUO Y M. Development of cell-penetrating peptide applying as a vector in molecular imaging . Med Imaging, 2008, 18(5):565-568.
[6]
ZAHID M, LU X, MI Z, et al. Cationic and tissue-specific protein transduction domains identification, characterization, and therapeutic application. Adv Genet, 2010,69(4):83-95.
[7]
CHUGH A, EUDES F, SHIM Y S. Cell-penetrating peptides: Nanocarrier for macromolecule delivery in living cells. UBMB Life, 2010, 62(3): 183-193.
[8]
TAKECHI Y, TANAKA H, KATAYAMA H, et al. Comparative study on the interaction of cell-penetrating polycationic polymers with lipid membranes. Chem Phys Lipids, 2012,165(1):51-58.
[9]
SUHORUTSENKO J, OSKOLKOV N, ARUKUUSK P, et al. Cell-penetrating peptides, pepFects, show no evidence of toxicity and immunogenicity in vitro and in vivo. Bioconjug Chem, 2011,22(11):2255-2262.
[10]
DESHAYES S, DECAFFMEYER M, BRASSEUR R, et al. Structural polymorphism of two CPPS: An important parameter of activity. Biochim Biophys Acta Biomembr, 2008,1778(5): 1197-1205.
[11]
LIU L H, GUO K, LU J, et al. Biologically active core/shell nanoparticles self-assembled from cholesterol-terminated PEG-TAT for drug delivery across the blood-brain barrier .Biomaterials, 2008, 29(10): 1509-1517.
[12]
QIN Y, CHEN H, YUAN W, et al. Liposome formulated with TAT-modified cholesterol for enhancing the brain delivery. Int J Pharm,2011,419(1-2):85-95.
[13]
TIAN X H, WEI F, WANG T X, et al. Blood-brain barrier transport of Tat peptide and polyethylene glycol decorated gelatin-siloxane nanoparticle. Materials Letters, 2012, 68(1): 94-96.
[14]
HAN L, ZHANG A L, WANG H J. Tat-BMPs-PAMAM conjugates enhance therapeutic effect of small interference RNA on U251 glioma cells in vitro and in vivo. Human Gene Therapy, 2010,21(4):417-426.
[15]
LIU H, LI W, AHMAD M, et al. Modification of ubiquitin-C-terminal hydrolase-L1 by cyclopentenone prostaglandins exacerbates hypoxic injury. Neurobiol Dis, 2011,41(2):318-328.
[16]
GAO Y, LIANG W, HU X, et al. Neuroprotection against hypoxic-ischemic brain injury by inhibiting the apoptotic protease activating factor-1 pathway. Stroke, 2010,41(1):166-172.
[17]
CAI B, LIN Y, XUE X H, et al. TAT-mediated delivery of neuroglobin protects against focal cerebral ischemia in mice. Experimental Neurology, 2011, 227(1):224-231.
[18]
DOEPPNER T R, DIETZ G P, WEISE J, et al. Protection of hippocampal neurogenesis by TAT-Bcl-x(L) after cerebral ischemia in mice. Exp Neurol,2010, 223(2):548-556.
[19]
DOEPPNER T R, EL A M, DIETZ G P H, et al. Transplantation of TAT-Bcl-xL-transduced neural precursor cells: Long-term neuroprotection after stroke. Neurobiol Dis,2010,40(1):265-276.
[20]
GOU X, WANG Q, YANG Q, et al. TAT-NEP1-40 as a novel therapeutic candidate for axonal regeneration and functional recovery after stroke. Drug Target, 2011,19(2):86-95.
[21]
BU X, ZHANG N, YANG X, et al. Proteomic analysis of cPKCbetaII-interacting proteins involved in HPC-induced neuroprotection against cerebral ischemia of mice. Neurochem,2011,117(2): 346-356.
[22]
MANFREDI R, FULGARO C, SABBATANI S, et al. Emergence of amphotericin B-resistant Cryptococcus laurentii meningoencephalitis shortly after treatment for Cryptococcus neoformans meningitis in a patient with AIDS.AIDS Patient Care STDS, 2006,20(4):227-232.
[23]
WANG H Y , XU K J, LIU L H, et al. The efficacy of self-assembled cationic antimicrobial peptide nanoparticles against Cryptococcus neoformans for the treatment of meningitis. Biomaterials, 2010,31(10): 2874-2881.
[24]
LIU L H, XU K J, WANG H Y, et al. Self-assembled cationic peptide nanoparticles as an efficient antimicrobial agent. Nat Nano Technol, 2009,4(7):457-463.
[25]
XU K, WANG H, LIU L, et al. Efficacy of CG(3)R(6)TAT nanoparticles self-assembled from a novel antimicrobial peptide for the treatment of candida albicans meningitis in rabbits. Chemotherapy,2011,57(5):417-425.
[26]
DIETZ G P, VALBUENA P C, DIETZ B, et al. Application of a blood brain barrier penetrating form of GDNF in a mouse model for Parkinson′s disease. Brain Res, 2006, 1082(1):61-66.
[27]
VAN DEN BERG A, DOWDY S F. Protein transduction domain delivery of therapeutic macromolecules. Current Opinion in Biotechnology, 2011, 22(6):1-6.
[28]
SIMON M J, GAO S, KANG W H, et al. Tat-mediated intracellular protein delivery to primary brain cells is dependent on glycosaminoglycan expression. Biotechnol Bioeng, 2009,104:10-19.
[29]
SIMON M J, GAO S, KANG W H. TAT-mediated intracellular protein delivery toprimary brain cells is dependent onglycosaminoglycan expression. Biotechnol Bioeng, 2009,104(1): 10-19.
[30]
SUBRIZI A,TUOMINEN E, BUNKER A, et al. Tat(48-60) peptide amino acid sequence is not unique in its cell penetrating properties and cellsurface glycosaminoglycans inhibit its cellular uptake .J Controlled Release,2012, 10;158(2):277-285.
[31]
MA D X, SHI N Q, QI X R. Distinct transduction modes of arginine-rich cell-penetrating peptides for cargo delivery into tumor cells. Inter J Pharm,2011,419(1-2):200- 208.
[32]
LO S L, WANG S. An endosomolytic Tat peptide produced by incorporation of histidine and cysteine residues as a nonviral vector for DNA transfection. Biomaterials, 2008, 29(15): 2408-2414.
[33]
YAMAGUCHI K, INOUE M, GOSHIMA N. Efficient protein transduction method using cationic peptides and lipids . J Biomed Biotechnol, 2011:872065. Epub 2011 Oct 9.
[34]
WEISS N, MILLER F, CAZAUBON S, et al. The blood-brain barrier in brain homeostasis and neurological diseases. Biochim Biophys Acta,2009,1788(4):842-857.
[35]
SIMON M J, KANG W H, GAO S, et al. TAT is not capable of transcellular delivery across an intact endothelial monolayer in vitro. Annals of Biomedical Engineering.Vol.2011, 39(1):394-401.
[36]
CHEN Y, LIU L. Modern methods for delivery of drugs across the blood-brain barrier. Adv Drug Deliv Rev, 2012,64(7) :640-665.
2013, Vol. 48 
